MoCRA FDA Software vs a Compliance Consultant: Which Should a Small Brand Use?

Search "MoCRA compliance" and two kinds of offer show up. Software platforms promise to make FDA facility registration and product listing painless. Consultants offer to handle MoCRA end to end. Both can be useful. The useful question for a small brand is not "which is best" but "which problem do I actually have?"

Formatting a listing correctly is one problem. Knowing whether the product can lawfully be listed as a cosmetic at all is a different — and more expensive — one. UK and EU brands who already live inside the Cosmetics Regulation often underestimate the second. Phoenix runs a MoCRA product listing service from Florida, so we have a horse in this race. We have tried to keep the comparison honest.

Start with what the FDA gives you for free

MoCRA — the Modernization of Cosmetics Regulation Act of 2022 — amended the Federal Food, Drug, and Cosmetic Act and gave FDA new duties and powers over cosmetics. Facility registration and product listing under section 607 go through Cosmetics Direct, FDA's own free portal. It walks you through the forms, builds the Structured Product Labeling (SPL) file FDA expects, runs basic validation and returns facility and listing numbers. A brand with one manufacturing site and a handful of simple cosmetics can finish registrations and listings there without paying a vendor, if someone is willing to learn the screens and the data is ready.

Third-party software and consultants do not replace Cosmetics Direct. They submit through it, or prepare SPL files that end up there (or via ESG NextGen). If a vendor implies you need their platform because FDA has no free option, that is marketing, not regulation. For the nuts and bolts of who registers, who lists and what goes in each filing, see our live guide to MoCRA product listing and facility registration.

What MoCRA software actually does

• Data capture and formatting. Guides you through FDA's required fields and produces valid submissions, cutting down formatting rejections.
• Ingredient nomenclature. Helps map names toward the conventions FDA expects, which are not always identical to EU INCI practice.
• Bulk and variant handling. Useful when you are listing dozens of SKUs or many shades and manual entry would drag on for days.
• Renewals and reminders. Tracks the two-year facility renewal and the annual listing update so filings do not quietly lapse.
• Records. Keeps submission history and listing numbers in one place.
• Sometimes adverse-event logging. A few platforms add a module for serious adverse events and the 15-business-day reporting clock. Logging is not the same as deciding what must be reported.

Those are real process benefits for a large catalogue or an in-house compliance person. None of them is a regulatory decision.

What software cannot do

Software takes the product you describe and files it. It does not ask whether that product should be filed as a cosmetic. In the US, sunscreen, acne, dandruff and antiperspirant products that make drug claims are OTC drugs under a different regime. Listing them as cosmetics does not convert them. Skin-lightening claims that affect structure or function raise the same trap.

Software also will not tell you whether an ingredient allowed in the UK is restricted or barred in the US, whether a colour additive is approved for the intended use (including eye area), whether your safety substantiation would satisfy a qualified expert, or whether the responsible person on the label is the right entity. It cannot read your marketing copy.

MoCRA's small-business exemption is another blind spot. Qualifying businesses can be excused from facility registration, product listing and GMP — but the exemption does not cover serious adverse event reporting or safety substantiation, and it falls away for products that regularly contact the eye's mucous membrane, are injected, are intended for internal use, or alter appearance for more than 24 hours without consumer removal. A mascara brand that assumes "we are small, so we are exempt" and never lists is making a judgement error no portal will catch.

A perfectly formatted listing of a drug, or of a product with a prohibited colour additive, is worse than no listing. It documents the mistake. FDA does not pre-approve cosmetics; accepting an SPL file is not a safety review.

What a consultant adds

• Classification. Confirming each product is a cosmetic in US terms and flagging claims that push it into OTC drug territory.
• Ingredient and colour-additive review. Checking every material against US restrictions and approved uses.
• Label review. Converting a UK or EU label toward US format: ingredient declaration, net contents, responsible-person contact for adverse events, warnings and professional-use statements where needed.
• Exemption analysis. Working out whether section 612 could apply and which SKUs sit outside it.
• Safety substantiation. Judging whether your CPSR and PIF adequately support the product as sold in the US, and closing gaps.
• Responsible person and US agent. Advising who should be named and arranging a US agent for a foreign facility.
• The submissions themselves. Registering the facility and listing products, often at a modest per-product fee once the decisions are made.
• Ongoing counsel. Serious adverse event reporting within 15 business days, follow-up information within a year of the first report, and watching the GMP and fragrance-allergen rules FDA is still writing.

What each typically costs

Cosmetics Direct is free. There is no FDA fee for registration or listing. Software is usually a subscription — tens to a few hundred dollars a month depending on catalogue size — which makes sense when you list many products or change them often, and less sense when you have three SKUs. Consultants typically split pricing: a fee for the initial regulatory review (the judgement work), then a per-product or batch fee for the filings (routine work). For a small brand, pay for the review; then file in Cosmetics Direct, through a listing service, or through software, whichever is cheapest for your volume.

The mistakes that actually cost money

• Listing a drug as a cosmetic. Sunscreen, acne, dandruff, antiperspirant and lightening claims are the usual culprits.
• Using a prohibited or restricted ingredient or colour additive. US colour-additive rules are stricter than many UK/EU brands expect, especially around the eye.
• Wrong responsible person on the label. Listing and adverse-event duties then attach to the wrong entity.
• Missing an exemption carve-out. Assuming small-business status while selling mascara or other eye-area products unlisted.
• Facility not registered. Listing products made in an unregistered contract facility.
• No US contact on the label. A labeling problem and a broken adverse-event channel.
• Treating a registration number as approval. FDA issues no compliance certificates; numbers prove a filing was accepted, not that the product is cleared.
• Letting registrations lapse. The two-year renewal is easy to miss without a reminder — this is the rare process error software actually prevents.

Only the last item is mainly a process failure. The rest are judgement failures software cannot see.

Where the two approaches meet

This is a division of labour, not a rivalry. Software executes decisions that have already been made correctly. A consultant is how those decisions get made. Skip the decisions and go straight to the tool, and you will execute mistakes efficiently. Pay a senior consultant to type routine listings by hand and you are buying clerical work at expert rates. The pattern that works for most small brands is a one-off expert review, a written record of the calls it produced, then the cheapest reliable execution route for the volume involved — with the consultant on call when a claim, product type, facility or rule changes.

Questions to ask a software vendor

• Does it submit directly to Cosmetics Direct, or produce SPL files for you to upload? Both are legitimate; know which you are buying.
• How does it handle ingredient nomenclature and colour additives it does not recognise?
• What happens when FDA changes the portal or validation rules? You want prompt updates and clear notices.
• Does it track two-year facility renewals and annual listing updates?
• Can you export your data if you leave?
• Does it include any regulatory review? Almost none do. Honest vendors say so.

Questions to ask a consultant

• Who will do the classification and ingredient review, and what are their qualifications?
• Will you review my label and claims for US compliance, not only format the listing?
• Can you act as, or arrange, a US agent for my foreign facility?
• How do you price the initial review versus ongoing listings?
• What do you need from me up front — CPSR, PIF, label, claims?
• What is your position on my sunscreen or acne SKU? If they will list it as a cosmetic without comment, walk away.

A realistic first year for a UK brand entering the US

Month one: commission a regulatory review of the range — classification, ingredients and colour additives, label and claims, exemption analysis, responsible person and US agent. Month two: update artwork with the US adverse-event contact, register the facility, appoint the US agent. Month three: list the products through the consultant, Cosmetics Direct or software, and stand up the adverse-event log with the 15-business-day clock. Through the year: log every adverse event, update listings when anything changes, diarise the annual listing update and the two-year facility renewal, and keep safety records current for the US version of each product. Most of the cost sits in month one. Most of the risk sits in skipping it.

A simple decision guide

Your situation	Sensible route
One to five simple products, no functional claims, US-based facility, comfortable with forms	Cosmetics Direct directly; still worth a one-off expert label and claims check
UK or EU brand entering the US for the first time	Expert review of classification, ingredients, label and exemption first; then list via consultant or portal
Any product with sun protection, acne, dandruff, antiperspirant or lightening claims	Consultant before anything else — some products cannot be listed as cosmetics
Eye-area, lip or long-wear colour cosmetics	Consultant to confirm exemption status and colour-additive compliance
Large catalogue, frequent changes, in-house compliance person	Software for volume and reminders, with periodic expert review
Contract-manufactured products	Confirm who registers the facility; expert review of who is the responsible person

Reusing your UK and EU work

If you already hold a current CPSR and Product Information File, you are ahead on US safety substantiation. MoCRA requires the responsible person to ensure and keep records showing adequate substantiation; it does not prescribe a UK-style report format. A solid CPSR plus PIF usually carries over well for the same formula sold in the US, once claims and labelling match the US version.

ISO 22716-style GMP documentation is still useful while FDA writes the MoCRA GMP regulations — those rules are not final yet. Fragrance-allergen labelling under MoCRA is likewise still being developed. MoCRA also preempts some conflicting state and local cosmetic safety and adverse-event rules, which reduces the patchwork UK brands used to fear. What still needs a US-specific pass is label format, claims, a handful of ingredient and colour-additive differences, the responsible-person contact, and the registration and listing mechanics. That is bounded expert work. After it, routine listings are genuinely routine.

A regulatory consultation is an efficient way to scope the gap. The MoCRA listing service handles the Cosmetics Direct filings once the decisions are made.

Related reading on the Phoenix blog

• MoCRA product listing and facility registration explained
• PIF vs CPSR: what goes where
• CPSR example: what a finished safety report looks like
• All regulatory compliance articles

Phoenix services mentioned in this article

• FDA MoCRA product listing for cosmetic products
• Cosmetic Product Safety Report, single variant
• Product Information File service
• Expert regulatory consultation
• Contact Phoenix

Official sources

• FDA: Modernization of Cosmetics Regulation Act of 2022 (MoCRA)
• FDA: Registration & Listing of Cosmetic Product Facilities and Products
• FDA Cosmetics Direct
• FDA cosmetics home

Disclaimer: This article is general information, not legal advice. MoCRA implementation and FDA guidance change. Product decisions depend on your exact formula, claims, facilities and label. Have your range reviewed by a qualified professional before US sale.

Myths we hear

• MoCRA only applies to US brands. Any facility that manufactures or processes cosmetics for US distribution must register — including foreign sites, which also need a US agent.
• Small businesses are fully exempt from MoCRA. Qualifying small businesses (under the FD&C Act section 612 sales threshold) can be exempt from facility registration, product listing and GMP. They are not exempt from serious adverse event reporting or safety substantiation, and eye-area, injectable, internal-use and certain long-wear products lose the exemption.
• Paying for MoCRA software means you are compliant. Software helps you file cleanly. You still need correct classification, allowed ingredients, a US-ready label, adequate safety records and a working adverse-event process.
• An FDA facility registration or product listing number is FDA approval. Registration and listing are inventory filings. FDA does not pre-approve cosmetics, and it does not issue certificates proving you are registered or listed.
• If Cosmetics Direct accepts the submission, the product must be fine to sell as a cosmetic. The portal checks format, not whether your claims make the product an OTC drug or whether an ingredient is permitted for that use.

What to do this week

1. Confirm each SKU is a cosmetic under US rules — flag sunscreen, acne, dandruff, antiperspirant or lightening claims before listing.
2. Check whether the small-business exemption could apply, and whether eye-area or other carve-outs knock you out of it.
3. Register manufacturing facilities and list products through Cosmetics Direct (or via a service that submits there); renew registration every two years and update listings annually.
4. Name the correct responsible person on the label, add a US contact for adverse event reports, and for foreign facilities appoint a US agent.
5. Keep records that adequately substantiate safety for the product as sold in the US.
6. Set up a serious adverse event log with a 15-business-day FDA reporting clock — software does not replace that duty.

Frequently asked questions

Official sources and legislation

• FDA: Modernization of Cosmetics Regulation Act of 2022 (MoCRA)
• FDA: Registration & Listing of Cosmetic Product Facilities and Products
• FDA Cosmetics Direct (free portal)
• FDA cosmetics home